Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H14N4O3 |
Molecular Weight | 238.2432 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)CN1C=NC2=C1C(=O)N(C)C(=O)N2C
InChI
InChIKey=KYHQZNGJUGFTGR-UHFFFAOYSA-N
InChI=1S/C10H14N4O3/c1-6(15)4-14-5-11-8-7(14)9(16)13(3)10(17)12(8)2/h5-6,15H,4H2,1-3H3
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/6291318Curator's Comment: description was created based on several sources, including
http://www.ndrugs.com/?s=ephedrine/proxyphylline
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6291318
Curator's Comment: description was created based on several sources, including
http://www.ndrugs.com/?s=ephedrine/proxyphylline
Proxyphylline is a xanthine derivative that acts as a cardiac stimulant, vasodilator and bronchodilator. In combination with ephedrine it’s used for relief of acute bronchial asthma and for reversible bronchospasm associated with chronic bronchitis and emphysema. Proxyphylline is readily absorbed from the gastrointestinal tract and it’s not converted to theophylline in the body. The clinical studies are agreed with the property of proxyphylline to inhibit the cyclic nucleotide phosphodiesterases.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363066 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6291318 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Novofilin Approved UseUnknown |
|||
Secondary | Unknown Approved UseUnknown |
|||
Secondary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Effectiveness of proxyphylline in chronic obstructive pulmonary disease (author's transl)]. | 1980 Jun 20 |
|
Antianaphylactic and antiasthmatic properties of new piperazinyl 7-(beta-hydroxypropyl)-theophylline derivatives in guinea pigs. | 2001 Mar-Apr |
|
Application of micellar electrokinetic chromatography to the quality control of a pharmaceutical preparation containing three bronchodilators. | 2002 Feb |
|
Surface crosslinking for delayed release of proxyphylline from PHEMA hydrogels. | 2008 Feb 12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7202475
intravenous: 29 mumol/kg
single oral: 21 mumol/kg and multiple oral: 21 mumol/kg three times a day
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6291318
Inhibition of cAMP and cGMP hydrolysis in human lung tissue by proxyphylline and its main metabolite 1-methyl-7-(beta-hydroxypropyl)xanthine was compared with theophylline and its metabolite 3-methylxanthine. The Inhibition constant of proxyphylline was 0.06-0.7 mmol/l at low cAMP concentrations and at low and high cGMP concentrations, while it was 1.0 mmol/l at high cAMP concentrations
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R03DA03
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
||
|
WHO-VATC |
QR03DB03
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
||
|
WHO-VATC |
QR03DA03
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
||
|
WHO-ATC |
R03DB03
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
||
|
NCI_THESAURUS |
C319
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
||
|
NCI_THESAURUS |
C744
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
86480-51-5
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
SUPERSEDED | |||
|
210-028-7
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
C80339
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL37390
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
34906
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
m9284
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
PROXYPHYLLINE
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
SUB10153MIG
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
4977
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
C003237
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
DB13449
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
969
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
163343
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
100000080861
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
603-00-9
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
DTXSID5023536
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
13G1DMN4P0
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY | |||
|
2323
Created by
admin on Fri Dec 15 16:11:30 GMT 2023 , Edited by admin on Fri Dec 15 16:11:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY